How (KROS) Movements Inform Risk Allocation Models
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) movements, highlighting weak near-term and long-term sentiment with a neutral mid-term outlook. It identifies an exceptional 89.7:1 risk-reward short setup and provides three institutional trading strategies tailored for different risk profiles and holding periods, based on AI model analysis. The strategies include position, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels.
Keros Therapeutics Inc (KROS-Q) Stock Price and News
This article provides stock information and recent news for Keros Therapeutics Inc (KROS-Q), a clinical-stage biopharmaceutical company focused on hematological and musculoskeletal disorders. It highlights recent news about their drug trials, financial updates, analyst ratings, and executive changes. The company's pipeline includes KER-050, KER-047, and KER-012, all in clinical stages.
Keros Therapeutics, Inc. (KROS) Stock Price, News, Quote & History
Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on developing therapies for disorders related to dysfunctional signaling of the TGF-beta family of proteins. The company's stock closed at $11.36, with a year-to-date return of -44.20%. Analysts have an average target price of $19.83 for KROS.
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Keros Therapeutics is set to receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the ELRiSE MF clinical trial for elritercept, a drug designed to treat myelofibrosis with anemia. This payment is part of a larger global license agreement that could see Keros receive over $1.1 billion in milestones and royalties. Keros plans to distribute 25% of the net cash proceeds from this milestone payment to its stockholders.
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics has dosed the first patient in a Phase II study for rinvatercept, its lead pipeline candidate for Duchenne muscular dystrophy (DMD). The study aims to evaluate the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory DMD patients, with initial data expected in the first half of 2027. Keros is also developing elritercept for cytopenias, having recently received a $20 million milestone payment from Takeda for its Phase III ELRiSE MDS study.
Keros Therapeutics to receive $20M milestone from Takeda
Keros Therapeutics (NASDAQ:KROS) announced it is set to receive a $20 million development milestone payment from its partner Takeda. This payment follows the dosing of the first patient in the ELRiSE MF clinical trial, a Phase 3 study for patients with myelofibrosis and anemia. The milestone is part of a global license agreement that could yield Keros over $1.1 billion in development, commercial, and sales milestones, in addition to royalties on net sales.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics has announced the first patient has been dosed in its Phase 2 clinical trial for rinvatercept, a novel therapeutic designed to treat Duchenne muscular dystrophy (DMD). Rinvatercept aims to modulate key regulators of muscle and bone biology to improve muscle regeneration and strength. Initial data from the trial is expected in the first half of 2027, representing a significant step in addressing the ongoing need for DMD treatment options.
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
Keros Therapeutics anticipates a $20 million milestone payment from Takeda. This payment is related to a development milestone, as announced by Keros Therapeutics on Tuesday.
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages
Keros Therapeutics (NASDAQ:KROS) has an average target price of $20.50 from brokerages, with analysts giving it a "Hold" consensus based on four buy, four hold, and one sell rating. The company recently reported quarterly adjusted earnings of -$1.45 per share, missing consensus, and has authorized a $5 million stock buyback. Institutional investors hold 71.56% of the stock, while insiders have sold approximately $55,000 worth of shares in the last three months.
The first patient has received a drug being tested for Duchenne muscular dystrophy. Initial data are expected in 2027.
Keros Therapeutics has dosed the first patient in its Phase 2 clinical trial evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The company anticipates initial trial data to be available in the first half of 2027. Rinvatercept is designed to modulate proteins involved in muscle and bone biology, and this trial aims to assess its potential impact on both ambulatory and non-ambulatory DMD patients.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics has initiated a Phase 2 clinical trial for rinvatercept in patients with Duchenne muscular dystrophy (DMD), with the first patient successfully dosed. Rinvatercept is designed to modulate key regulators of muscle and bone biology by acting as a ligand trap for myostatin and activin A, aiming to improve muscle regeneration, strength, and overall bone health. Initial data from this trial is anticipated in the first half of 2027, representing a significant step in Keros's neuromuscular development strategy.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics announced the first patient has been dosed in its Phase 2 clinical trial for rinvatercept, a novel therapeutic designed to treat Duchenne muscular dystrophy (DMD). The drug aims to modulate key regulators of muscle and bone biology, with initial data expected in the first half of 2027. This open-label, multi-cohort basket trial will assess the safety, tolerability, pharmacokinetics, and functional improvements of rinvatercept in both ambulatory and non-ambulatory DMD patients.
Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential
Keros Therapeutics, Inc. (KROS) is highlighted as a compelling investment opportunity in the biotechnology sector, boasting a potential upside of 74.59%. The company, a clinical-stage biopharmaceutical firm, is developing therapeutics for disorders related to transforming growth factor-beta family proteins. Despite not yet being profitable, its innovative pipeline, strategic collaborations with Hansoh and Takeda, and favorable analyst ratings position it as a noteworthy stock for long-term growth-oriented investors.
Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026)
This article reports on an SEC filing by Keros Therapeutics, Inc. (KROS) related to the effectiveness of a Shelf Registration Statement (Form S-3) on September 16, 2026. The filing indicates a neutral impact and sentiment according to AI analysis, and the article also provides recent news and SEC filing history for the company.
(KROS) Volatility Zones as Tactical Triggers
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) through volatility zones, identifying stable neutral readings in shorter horizons and a mid-channel oscillation pattern. It highlights an exceptional 95.3:1 risk-reward setup targeting a 29.6% gain, alongside neutral sentiment. The analysis provides specific institutional trading strategies for long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis.
Bank of New York Mellon Corp Takes $1.11 Million Position in Keros Therapeutics, Inc. $KROS
Bank of New York Mellon Corp has acquired a new position in Keros Therapeutics, Inc., purchasing 103,339 shares valued at approximately $1.11 million. This comes as Keros Therapeutics reported a quarterly loss worse than anticipated and authorized a $5 million share repurchase program. Analysts currently maintain a "Hold" rating on the stock with an average price target of $20.50.
Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors
Keros Therapeutics' Board of Directors has approved a $5 million share repurchase program, authorizing the company to buy back up to 2.3% of its outstanding shares. This decision comes as KROS shares trade near the midpoint of their 52-week range, despite the company reporting a wider-than-expected quarterly loss. Analyst sentiment for Keros Therapeutics remains mixed, with an average "Hold" rating and a price target of $20.50, though some recent targets have been lowered.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics has announced a $5 million share repurchase program for its common stock. This authorization follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. The timing and amount of repurchases will depend on market conditions and other factors, and the program can be modified or discontinued at any time.
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.
Keros Therapeutics, Inc. has announced a share repurchase program, authorizing the buyback of up to $5 million worth of its common stock. This decision was published on September 8, 2026, at 04:03 pm EDT. The biotechnology company focuses on developing therapeutics for disorders related to dysfunctional TGF-beta family proteins.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million milestone payment from Takeda Pharmaceuticals for elritercept's ELRiSE MDS clinical trial. The program allows Keros to repurchase common stock in the open market, with timing and amount dependent on market conditions and other factors. Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders related to dysfunctional TGF-ß family proteins.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics has announced a $5 million share repurchase program for its common stock. This decision follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals, triggered by the first patient dosing in the ELRiSE MDS clinical trial for elritercept. The program allows management to repurchase shares in the open market, with timing and amounts dependent on various market and economic factors.
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18
Wells Fargo has reiterated its Buy rating on Keros Therapeutics (KROS.US) and maintained a target price of $18. This indicates the firm's continued positive outlook on the company's stock performance.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts
Keros Therapeutics (NASDAQ:KROS) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $20.50 against its current price of $11.11. The company reported a wider-than-expected quarterly loss of $1.45 per share, and analysts anticipate a full-year loss of $5.27 per share. While institutional ownership is high at 71.56%, insiders have recently sold shares.
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS
Empowered Funds LLC has acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) by purchasing 142,151 shares valued at approximately $1.52 million during the second quarter of 2026. This investment makes Empowered Funds LLC a 0.72% owner of Keros Therapeutics, a company where institutional investors collectively hold 71.56% of the stock. Keros Therapeutics recently reported a quarterly loss that missed analyst expectations, and despite mixed analyst ratings, the stock holds an overall "Hold" consensus with an average price target of $20.50.
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com
Keros Therapeutics director Jean Jacques Bienaime recently purchased 1,000 shares of the company's common stock for a total of $10,270. This insider buying occurred near the stock's 52-week low, with InvestingPro analysis suggesting the stock is undervalued and highlighting the company's strong current ratio and cash position despite burning through cash quickly. Additionally, Keros Therapeutics appointed Anne Prener to its board of directors, further strengthening its leadership team.
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS
Man Group plc recently acquired 155,541 shares of Keros Therapeutics (NASDAQ:KROS), valued at approximately $1.66 million, bringing institutional ownership in Keros to 71.56%. Keros Therapeutics reported a quarterly loss of $1.45 per share, underperforming analyst expectations. Analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $20.50.
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS
BlackRock Inc. has acquired 2,794,217 shares of Keros Therapeutics (NASDAQ:KROS) worth approximately $29.9 million, giving it a 14.09% stake in the company. Institutional investors collectively own 71.56% of KROS, while insider transactions show recent sales totaling 13,768 shares. Analysts have a mixed sentiment, with a consensus "Hold" rating and a target price of $20.50, despite the company missing its last quarterly earnings estimates.
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. has acquired 127,885 shares of Keros Therapeutics, Inc. (NASDAQ:KROS) worth approximately $1.37 million, increasing institutional ownership to 71.56%. Despite this, the company faces financial pressure, reporting a quarterly loss below estimates and trading well below its 52-week high, leading to a mixed "Hold" rating from analysts with an average price target of $20.50. Insider selling has also occurred, with directors selling shares totaling over $56,000 in early June.
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research
Zacks Research upgraded Keros Therapeutics (NASDAQ:KROS) from "strong sell" to "hold," contributing to an overall analyst consensus of "Hold" with an average price target of $20.50. The company's shares opened at $11.03, trading near the lower end of their 52-week range, and Keros reported a quarterly loss of $1.45 per share, missing estimates. Insider transactions show directors selling shares, while institutional investors have adjusted their stakes in the company.
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS
Nantahala Capital Management LLC has acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS), purchasing over 1.41 million shares valued at approximately $15.1 million, which constitutes a 7.11% stake in the company. Institutional investors collectively own 71.56% of Keros Therapeutics. The article also notes recent insider selling activity, mixed analyst ratings resulting in a consensus "Hold" with an average price target of $20.50, and the company's recent earnings miss.
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com
Jean-Jacques Bienaime, a director at Keros Therapeutics, Inc., recently purchased 1,000 shares of KROS stock for a total of $10,270. This transaction was executed under a Rule 10b5-1 trading plan and increased his direct beneficial ownership to 19,592 shares. The company's stock is currently trading near its 52-week low, and InvestingPro analysis suggests it is undervalued, despite burning through cash.
ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS
ADAR1 Capital Management LLC has purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) during the second quarter, acquiring 246,818 shares valued at approximately $2.64 million. This makes ADAR1 Capital Management LLC the owner of about 1.24% of Keros Therapeutics' stock. Other institutional investors have also adjusted their holdings, and the article also details recent insider stock sales, Keros Therapeutics' financial performance, and current analyst ratings.
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros Therapeutics (KROS) reported a significant Q2 2026 loss and zero revenue, shifting investment focus heavily to its pipeline drug rinvatercept. While the company has a cash runway into H1 2028, its high valuation, intense competition in Duchenne muscular dystrophy, and dependence on a single lead asset raise concerns. Analysts suggest caution, given the current risk-reward profile and neutral short-term outlook.
Keros Therapeutics (NASDAQ:KROS) Raised to Sell at Wall Street Zen
Keros Therapeutics (NASDAQ:KROS) was upgraded by Wall Street Zen from a "strong sell" to a "sell" rating, though the overall analyst consensus remains "Hold" with a target price of $20.50. The company reported a quarterly loss of $1.45 per share, missing estimates, and its shares opened at $11.03, near the lower end of its 12-month range. Insider sales totaled nearly $145,000 in the past 90 days, while institutional investors hold 71.56% of the stock.
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock
Lorena Raquel Lerner, an insider at Keros Therapeutics (NASDAQ:KROS), sold 3,568 shares for $36,714.72 to cover tax withholding obligations related to vested equity awards, reducing her ownership by 11.46%. The company is facing weak financial performance with a recent quarterly loss and its stock trading near a 12-month low. Analyst ratings are mixed, with a consensus "Hold" and an average target price of $20.50.
Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock
Annita Tanini, VP at Keros Therapeutics, sold 1,224 shares of KROS stock worth $12,594.96 to cover tax withholding obligations on August 18th, 2026, reducing her stake by 2.64%. This insider sale comes amidst weak financial results, with the company missing earnings estimates and analysts projecting a full-year loss of $5.16 per share. Despite institutional ownership of 71.56% and an average analyst target of $20.50, the stock is trading significantly lower at $10.95, with mixed analyst ratings.
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale
Keros Therapeutics (NASDAQ: KROS) director Charles W. Newton has filed a Form 144 to sell 551 shares of common stock through UBS Financial Services Inc. These shares are related to restricted stock units (RSUs) with an indicated date of August 15, 2026. The filing also notes a previous sale of 550 shares on June 11, 2026.
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen
Keros Therapeutics (NASDAQ:KROS) has been downgraded to a "strong sell" rating by Wall Street Zen. This comes as the company's shares opened near their 52-week low and reported a larger-than-expected quarterly loss of $1.45 per share. Despite the downgrade, the broader analyst consensus for KROS remains "Hold" with an average price target of $20.50, and institutional investors hold a significant portion of the stock.
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Keros Therapeutics (NASDAQ:KROS) by 453.9% in the first quarter, now owning 1.62% of the company. Despite this institutional interest, Keros Therapeutics missed analyst expectations with a quarterly loss of $1.45 per share, and its stock remains well below its 52-week high. Analyst sentiment is mixed, with a consensus "Hold" rating, while company insiders have sold shares worth nearly $90,000 in the last 90 days.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside
Analysts have lowered the 12-month average price target for Keros Therapeutics, Inc. (KROS) stock from $20.33 to $19.83, with individual forecasts ranging from $16 to $25 per share. Despite the cut, this new target still suggests an 86% potential upside based on the Aug. 10 closing price. The consensus rating for KROS remains "Buy" among 8 analysts.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Keros Therapeutics (NASDAQ:KROS) has received an average "Hold" rating from analysts, with nine analysts providing coverage: four buy, three hold, and two sell recommendations. The average 12-month price target is $20.50, significantly higher than its current $11.15 price. Despite this, the company reported weaker-than-expected quarterly EPS of negative $1.45 and expects a full-year loss of $5.12 per share, while insiders have been selling shares, even as institutional investors hold a majority stake.
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen
Wall Street Zen has upgraded Keros Therapeutics (NASDAQ:KROS) from a "strong sell" to a "sell" rating, while other analysts remain divided with a consensus "Hold" rating and an average price target of $20.50. The company reported a Q2 EPS of -$1.45, missing estimates, and analysts anticipate a full-year loss of $5.12 per share. Insider transactions show recent sales, and institutional investors hold 71.56% of the stock as Keros continues developing therapies for anemia.
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS
Renaissance Technologies LLC has reduced its stake in Keros Therapeutics, Inc. by 23.4%, selling 138,204 shares and now owning 453,482 shares valued at approximately $5.0 million. This comes as Keros shares trade near their 52-week low, following a quarterly loss that missed analyst estimates and continued insider selling. Despite mixed analyst sentiment, with a consensus "Hold" rating and a $20.50 price target, the company faces challenges including unprofitability and dependence on future clinical progress.
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Keros Therapeutics announced its second-quarter 2026 financial results, reporting a net loss of $28.7 million, a decrease from the previous year, primarily due to lower R&D and general and administrative expenses. The company highlighted the initiation of its Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy and expects initial data in the first half of 2027. Keros also stated its cash and cash equivalents of $257.6 million are sufficient to fund operations into the first half of 2028.
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst
HC Wainwright has revised its FY2026 EPS estimate for Keros Therapeutics (NASDAQ:KROS), forecasting a smaller loss of $4.62 per share, an improvement from their previous estimate of a $5.12 loss. Despite this, the company faces mixed analyst sentiment with a consensus "Hold" rating and an average price target of $20.50, as several firms have recently lowered targets or downgraded the stock. Keros Therapeutics reported a quarterly loss of $1.45 per share, missing the consensus estimate, and has seen insider selling activity in recent months, though institutional investors hold a significant stake.
TD Cowen Maintains Keros Therapeutics(KROS.US) With Hold Rating
TD Cowen has reiterated its Hold rating on Keros Therapeutics (KROS.US). The article does not provide further details or a price target for the stock.
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than anticipated, with revenues falling to zero as the company has no marketed product. Despite the lack of revenue, Keros maintains a cash runway into the first half of 2028, supporting the development of its lead candidate, rinvatercept, which is in phase II trials for Duchenne muscular dystrophy and is also being explored for amyotrophic lateral sclerosis. The company's expenses decreased significantly due to a corporate restructuring and the transfer of development costs for another candidate, elritercept, to Takeda.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside
Keros Therapeutics, Inc.'s stock average price target has been reduced from $21.83 to $20.33 by 6 analysts, with a range of $16 to $25 per share. This new target suggests a potential 101% upside based on the August 3 closing price. The consensus rating for Keros Therapeutics remains "Buy" from 8 analysts.
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30
Leerink Partners has reduced its target price for Keros Therapeutics Inc (KROS.O) from $30 to $23. This adjustment reflects an analyst's revised outlook for the company. The article, sourced from Reuters, does not provide further details on the reasons behind the target price cut.
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS
Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings, reporting a loss of $1.45 per share, which missed the consensus estimate by $0.20. The company also posted negative returns on equity and net margin. KROS shares are trading near their one-year low, and analysts maintain a "Hold" rating with a target price of $20.40.
